Response to XIL Consulting’s “Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”
February 14, 2020
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
